Revance Therapeutics, Inc. (RVNC)

Revance Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Nashville, TN.

Address

1222 DEMONBREUN STREET
NASHVILLE, TN 37203

Founded

1999

Number of Employees

597

Website

http://www.revance.com

Buyback

Buyback Data 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 Average
$ Amount Purchased
($ in 000s )		 - $762 $981 $430 $1,908 $1,223 - - - - - $1,061
Average Price - $26.00 $20.18 $20.25 $32.26 $16.21 - - - - - $22.69
# Shares Purchased - 29,301 48,606 21,249 59,126 75,461 - - - - - 46,749
Buyback Performance 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 Average
Total Return to Date - -76.9% -70.3% -70.4% -81.4% -63.0% - - - - - -73.6%
S&P 500 Return to Date - 173.0% 168.6% 129.7% 104.9% 93.1% - - - - - 133.9%
Excess Total Return - -249.9% -238.9% -200.1% -186.3% -156.1% - - - - - -207.4%
Quartile Rank
Percentile Rank - 7% 8% 8% 4% 9% - - - - - 7%
Buyback returns calculated using weighted average buyback price over the last 10 years and comparing to current day stock price value. S&P 500 used as benchmark for excess return.

Insider Transactions

Filters

Keyboard Shortcuts: Show (a) | Close (Esc)

People also followed
Day One Biopharmaceuticals, Inc.
Amylyx Pharmaceuticals, Inc.
Akero Therapeutics, Inc.
XENCOR INC

Inmune Bio, Inc.